MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback